RCD news
The biopharmaceutical company, aptaTargets, reaches an agreement with Merck for the clinical development and commercialisation of the drug, ApTOLL
RCD has advised the biopharmaceutical company, aptaTargets, on an agreement with the German multinational pharmaceutical company Merck KGaA for the clinical development and commercialisation of ApTOLL, a Toll-like receptor 4 (TLR4) antagonist being developed for acute ischaemic stroke
The alliance provides the technical and financial resources necessary to accelerate the development of this innovative therapy for stroke patients. In a Phase 1b/2a clinical trial, ApTOLL demonstrated positive safety and efficacy results for acute ischemic stroke, including a reduction in mortality and improved functional recovery.
A team led by Oscar Alegre, Iñaki Silva, and David Pintos advised aptaTargets on this transaction.
